Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs

Health
By Christina Jewett from NYT Health https://ift.tt/WjOt3IX
via IFTTT United States International Relations, Drugs (Pharmaceuticals), Factories and Manufacturing, United States Politics and Government, Biotechnology and Bioengineering, Cystic Fibrosis, Cancer, Supply Chain, Intellectual Property, Shortages, Government Contracts and Procurement, Labor and Jobs, Start-ups, Leukemia, Research, Tax Credits, Deductions and Exemptions Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.

Comments

Popular posts from this blog

F.D.A. Poised to Restrict Access to Covid Vaccines

U.S. Will No Longer Recommend Covid Shots for Children and Pregnant Women